U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984146) titled 'Nivo40-AVD for Advanced Classic Hodgkin Lymphoma' on May 02.
Brief Summary: The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Hodgkin Lymphoma, Adult
Intervention:
DRUG: Nivolumab
40 mg day 1 and 15
DRUG: Doxorubicin
25 mg/m2 day 1 and 15
DRUG: Vinblastine
6 mg/m2 (not exceeding 10 mg) day 1 and 15
DRUG: Dacarbazine
375 mg/m2 day 1 and 15
Recruitment Status: RECRUITING
Sponsor: National Medical Resea...